FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2966126131> ?p ?o ?g. }

• W2966126131 endingPage "5825" @default.
• W2966126131 startingPage "5812" @default.
• W2966126131 abstract "Abstract Activating mutations in BRAF, a key mediator of RAS signaling, are present in approximately 50% of melanoma patients. Pharmacologic inhibition of BRAF or the downstream MAP kinase MEK is highly effective in treating BRAF-mutant melanoma. In contrast, RAS pathway inhibitors have been less effective in treating epithelial malignancies, such as lung cancer. Here, we show that treatment of melanoma patients with BRAF and MEK inhibitors (MEKi) activated tumor NF-κB activity. MEKi potentiated the response to TNFα, a potent activator of NF-κB. In both melanoma and lung cancer cells, MEKi increased cell-surface expression of TNFα receptor 1 (TNFR1), which enhanced NF-κB activation and augmented expression of genes regulated by TNFα and IFNγ. Screening of 289 targeted agents for the ability to increase TNFα and IFNγ target gene expression demonstrated that this was a general activity of inhibitors of MEK and ERK kinases. Treatment with MEKi led to acquisition of a novel vulnerability to TNFα and IFNγ-induced apoptosis in lung cancer cells that were refractory to MEKi killing and augmented cell-cycle arrest. Abolishing the expression of TNFR1 on lung cancer cells impaired the antitumor efficacy of MEKi, whereas the administration of TNFα and IFNγ in MEKi-treated mice enhanced the antitumor response. Furthermore, immunotherapeutics known to induce expression of these cytokines synergized with MEKi in eradicating tumors. These findings define a novel cytokine response modulatory function of MEKi that can be therapeutically exploited. Significance: Lung cancer cells are rendered sensitive to MEK inhibitors by TNFα and IFNγ, providing a strong mechanistic rationale for combining immunotherapeutics, such as checkpoint blockers, with MEK inhibitor therapy for lung cancer. See related commentary by Havel, p. 5699" @default.
• W2966126131 created "2019-08-13" @default.
• W2966126131 creator A5006968359 @default.
• W2966126131 creator A5012452779 @default.
• W2966126131 creator A5025170713 @default.
• W2966126131 creator A5032171890 @default.
• W2966126131 creator A5038938973 @default.
• W2966126131 creator A5039307865 @default.
• W2966126131 creator A5053258201 @default.
• W2966126131 creator A5053911309 @default.
• W2966126131 creator A5059758317 @default.
• W2966126131 creator A5064494204 @default.
• W2966126131 creator A5065698591 @default.
• W2966126131 creator A5087312293 @default.
• W2966126131 creator A5087340271 @default.
• W2966126131 date "2019-11-15" @default.
• W2966126131 modified "2023-09-23" @default.
• W2966126131 title "MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer" @default.
• W2966126131 cites W1580870868 @default.
• W2966126131 cites W1888783223 @default.
• W2966126131 cites W1974056979 @default.
• W2966126131 cites W1979334328 @default.
• W2966126131 cites W1985424846 @default.
• W2966126131 cites W1991401350 @default.
• W2966126131 cites W2001999652 @default.
• W2966126131 cites W2004962128 @default.
• W2966126131 cites W2006354480 @default.
• W2966126131 cites W2035057964 @default.
• W2966126131 cites W2039123767 @default.
• W2966126131 cites W2042699075 @default.
• W2966126131 cites W2062983115 @default.
• W2966126131 cites W2080641261 @default.
• W2966126131 cites W2084281756 @default.
• W2966126131 cites W2086434836 @default.
• W2966126131 cites W2093463728 @default.
• W2966126131 cites W2099044540 @default.
• W2966126131 cites W2099257830 @default.
• W2966126131 cites W2114903025 @default.
• W2966126131 cites W2122757240 @default.
• W2966126131 cites W2124427232 @default.
• W2966126131 cites W2127437403 @default.
• W2966126131 cites W2129036849 @default.
• W2966126131 cites W2135708326 @default.
• W2966126131 cites W2144096834 @default.
• W2966126131 cites W2148157688 @default.
• W2966126131 cites W2160371778 @default.
• W2966126131 cites W2160586729 @default.
• W2966126131 cites W2289851792 @default.
• W2966126131 cites W2296591944 @default.
• W2966126131 cites W2560367415 @default.
• W2966126131 cites W2562693435 @default.
• W2966126131 cites W2597182072 @default.
• W2966126131 cites W2765585947 @default.
• W2966126131 cites W2776458885 @default.
• W2966126131 cites W2787787845 @default.
• W2966126131 doi "https://doi.org/10.1158/0008-5472.can-19-0698" @default.
• W2966126131 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6881545" @default.
• W2966126131 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31362929" @default.
• W2966126131 hasPublicationYear "2019" @default.
• W2966126131 type Work @default.
• W2966126131 sameAs 2966126131 @default.
• W2966126131 citedByCount "5" @default.
• W2966126131 countsByYear W29661261312019 @default.
• W2966126131 countsByYear W29661261312020 @default.
• W2966126131 countsByYear W29661261312021 @default.
• W2966126131 countsByYear W29661261312022 @default.
• W2966126131 countsByYear W29661261312023 @default.
• W2966126131 crossrefType "journal-article" @default.
• W2966126131 hasAuthorship W2966126131A5006968359 @default.
• W2966126131 hasAuthorship W2966126131A5012452779 @default.
• W2966126131 hasAuthorship W2966126131A5025170713 @default.
• W2966126131 hasAuthorship W2966126131A5032171890 @default.
• W2966126131 hasAuthorship W2966126131A5038938973 @default.
• W2966126131 hasAuthorship W2966126131A5039307865 @default.
• W2966126131 hasAuthorship W2966126131A5053258201 @default.
• W2966126131 hasAuthorship W2966126131A5053911309 @default.
• W2966126131 hasAuthorship W2966126131A5059758317 @default.
• W2966126131 hasAuthorship W2966126131A5064494204 @default.
• W2966126131 hasAuthorship W2966126131A5065698591 @default.
• W2966126131 hasAuthorship W2966126131A5087312293 @default.
• W2966126131 hasAuthorship W2966126131A5087340271 @default.
• W2966126131 hasBestOaLocation W29661261311 @default.
• W2966126131 hasConcept C121608353 @default.
• W2966126131 hasConcept C126322002 @default.
• W2966126131 hasConcept C17991360 @default.
• W2966126131 hasConcept C184235292 @default.
• W2966126131 hasConcept C203014093 @default.
• W2966126131 hasConcept C2776256026 @default.
• W2966126131 hasConcept C2777658100 @default.
• W2966126131 hasConcept C2778690821 @default.
• W2966126131 hasConcept C2781249067 @default.
• W2966126131 hasConcept C502942594 @default.
• W2966126131 hasConcept C57074206 @default.
• W2966126131 hasConcept C71924100 @default.
• W2966126131 hasConcept C86803240 @default.
• W2966126131 hasConcept C95444343 @default.
• W2966126131 hasConcept C98274493 @default.
• W2966126131 hasConceptScore W2966126131C121608353 @default.

• next